Jonathan Friedberg

Academic History

Jonathan Friedberg, MD, MMSc, obtained his medical degree from Harvard Medical School, Boston, MA in 1994. He then went on to do an internship and residency at Massachusetts General Hospital, Boston, MA, before undergoing a Hematology & Oncology Fellowship at the Dana-Farber Cancer Institute, Boston, MA. Dr Friedberg also has an MMSc degree in clinical investigation from Harvard Medical School.

Dr Friedberg is currently the Director of the Wilmot Cancer Institute and the Samuel Durand Professor of Medicine at the University of Rochester Medical Center, Rochester, NY. In June 2021, he began his five-year term as the editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO).

Speaking on novel therapies and unmet needs in lymphoma

Dr Friedberg is actively involved in research that aims to develop novel treatments and therapeutic strategies for patients with lymphoma, acting as the principal investigator on various clinical trials. He is a chair of the lymphoma committee in the SWOG group of the NCI National Clinical Trials Network and co-leader of the current North American intergroup effort in advanced stage Hodgkin lymphoma. Dr Friedberg has won numerous awards throughout his career, including a Scholar in Clinical Research award from the Leukemia & Lymphoma Society. He received this award for his research into an oral Syk inhibitor, which demonstrated efficacy in several different lymphoma subtypes.